HER2/neu peptide vaccine: Additional Phase I data

TapImmune Inc. (OTCBB:TPIV, Seattle, Wash.) said data from 20 evaluable previously treated patients with HER2-positive stage II/III breast cancer in an open-label, U.S. Phase I trial showed that 6 in...